expiration cutting sales like eli lilly's cymbalta and lexapro. drug makers backed away from cns disorders in recent years as proved difficult more than other areas. the top drug development, the medicine take more than a yearlonger to develop and half as likely to be approved for drugs than other diseases. why? the disorders are complex and misunderstood. hard to measure. >> in a trial, you could see x-ray and mri. objectively see whether it's growing or shrinking. psychiatry the end point is determining whether the drug works or not is questions about how they feel. >> reporter: stocks soared today to start a late stage trial of schizophrenia drug later this year. helped the weight gain with therapies for the disorder a side effect to lead patients to stop taking the drugs. a late stage medicine for depression boosted the shares. for "nightly business report," i'm meg terrell. >>> a weak forecast sent shares of eli lily down and that's where we begin market focus. the drug maker struggled because of competition from generics and expecting 2015 e